Associate Director, Program Management
Alnylam Pharmaceuticals | |
United States, Massachusetts, Cambridge | |
675 West Kendall Street (Show on map) | |
Oct 19, 2024 | |
This role is considered Hybrid. Overview At Alnylam, preclinical-stage programs are managed by Early Program Leadership Teams, led by a Program Leader and a Program Manager, responsible for harnessing cross-functional expertise to define the best scientific, clinical, and commercial strategies and plans for the success of the Program. The role of the Associate Director, Program Management is to partner with Research Target Champions and Program Leaders of the portfolio to drive program strategy and execution of various assets in the early development portfolio. The candidate will be responsible for providing a combination of drug development, stewardship, and program expertise to the Program Leadership Teams. This role, through partnership with the Research and Program Leaders, has significant responsibility for developing, driving, operationalizing, and executing the program strategy.In this role, the candidate will be required to work closely with development stage appropriate sub -teams for each program such as Research working groups, Clinical Development Sub-teams (CDST), the Tech Ops & Quality (TOQ) Sub-team, Early Development (eDev) Sub-team and Collaboration Partners as part of the overall Program Leadership Team. The candidate will also be responsible for driving the identification/implementation of Program Management best practices within Alnylam.In this capacity, the candidate will call upon prior experience and program management insights to continually help the program management team increase its efficiency and value. This role reports to the Sr. Director, Head of Research and Early Development Program Management. This position is hybrid and will be primarily located in Cambridge, MA. Key Responsibilities
Qualifications
About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. > |